Subcutaneous Velcade approved in Europe for MM

The European Commission approved a subcutaneous formulation of Velcade bortezomib from Johnson & Johnson (NYSE:JNJ) to treat multiple myeloma (MM). An IV formulation of the small molecule dipeptide bo...